A Houston doctor’s work transformed leukemia treatment. Next up: Helping patients avoid chemotherapy
Over his more than four-decade career, Dr. Hagop Kantarjian has produced more than 2,000…
Related Articles
Insights into the etiology of Castleman disease
In this issue of Blood, Chan et al report on in-depth studies of identical twins with idiopathic multicentric Castleman disease (iMCD), which provides a un
4th How to Diagnose and Treat: CML/MPN | ESH – European School of Haematology
Chairs : Claire Harrison, Andreas Hochhaus, Ruben Mesa March 7-9, 2025 – Vienna, Austri Chairs: Claire Harrison, Andreas Hochhaus, Ruben Mesa ESH How to Diagnose…
BRAF mutation in myeloid neoplasm: incidences and clinical outcomes
The presence of BRAF mutation in hematological malignancies, excluding Hairy cell leukemia, and its significance as a driver mutation in myeloid neoplasms (MNs) remains largely…
Defining disease modification in myelofibrosis in the era of targeted therapy
There is a need to understand and define disease modification in myelofibrosis. This review examines the latest clinical data of targeted therapies for myelofibrosis and…
Royals rookie Hill thriving after beating cancer
DETROIT — Royals rookie left-hander Tim Hill looked in the mirror and hardly recognized himself. A skeleton, he thought. He needed to take a photo,…
Moving toward disease modification in polycythemia vera
Polycythemia vera is a BCR-ABL1–negative myeloproliferative neoplasm that reduces life expectancy through thrombosis, marrow failure, and transformation to leuk
Chernobyl and Biology: Dual Degree Prompts Alumni Award Winner to Pivot | School of Molecular & Cellular Biology | UIUC
Congratulations to Dr. Mesa, a 2024 College of Liberal Arts & Sciences Distinguished Alumni Award Recipient!
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123 – PubMed
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123
Hope for a Rare Disease: Myelofibrosis – The Bloodline with LLS
“If you have a rare disease, it’s not rare to you.” In this episode, Dr. Naveen Pemmaraju of MD Anderson Cancer Center in Houston, TX,…
Research To Practice | Oncology Videos: Blastic Plasmacytoid Dendritic Cell Neoplasm | Oncology Today with Dr Neil Love: Blastic Plasmacytoid Dendritic Cell Neoplasm
Featuring an interview with Prof Naveen Pemmaraju, including the following topics: Case: A woman in her mid 20s with classic blastic plasmacytoid dendritic cell neoplasm (BPDCN)…